– USA, CO – Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the appointment of Quentin Blackford to its Board of Directors.
“We are very excited to have Quentin join our Board of Directors. Quentin has one of the most impressive track records in high-growth med-tech, and has led some of the most successful medical device companies of the last decade. I look forward to partnering with Quentin to advance our mission of improving foot and ankle patient outcomes,” said CEO and Chairman, Albert DaCosta.
Quentin Blackford will also join the Compensation Committee as Chairman and the Audit Committee as a member.
About Quentin Blackford
Mr. Blackford has more than two decades of senior leadership experience with global medical device companies. He currently serves as President, CEO, and Director of iRhythm Technologies (NASDAQ: IRTC), a leading digital healthcare solutions company.
Before iRhythm Technologies, Mr. Blackford served at Dexcom, Inc. from 2017 to 2021, first as CFO and then as COO. Before Dexcom, Mr. Blackford served at Nuvasive, Inc. from 2009 to 2017, including as CFO and as Head of Strategy and Corporate Integrity from 2014 to 2017. Before 2009, Mr. Blackford served at Zimmer Biomet, Inc. (NYSE: ZBH) in various senior financial leadership positions. Since October 2017, Mr. Blackford has also served as a member of the board of directors of Alphatec Holdings, Inc. (NASDAQ: ATEC), where he serves on the compensation committee and audit committee.
Mr. Blackford is a Certified Public Accountant (inactive) and received dual Bachelor of Science degrees in Accounting and Business Administration from Grace College.
About Paragon 28, Inc.
Based in Englewood, Colo., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28 has provided innovative orthopedic solutions, procedural approaches, and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, hallux valgus (bunions), hammertoe, ankle, progressive collapsing foot deformity or flatfoot, Charcot foot, and orthobiologics. The company designs products with both the patient and surgeon in mind, to improve outcomes, reduce ailment recurrence and complication rates, and make the procedures simpler, consistent, and reproducible.
For more information: https://paragon28.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
